|
US4343794A
(en)
|
1980-05-06 |
1982-08-10 |
Mt. Sinai |
Method of reducing intraocular pressure with salts of vanadic acid
|
|
US4652586A
(en)
|
1980-11-07 |
1987-03-24 |
The General Hospital Corporation |
Selective beta-2 adrenergic antagonists for the treatment of glaucoma
|
|
US4617299A
(en)
|
1983-12-19 |
1986-10-14 |
Knepper Paul A |
Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
|
|
US5242943A
(en)
|
1984-03-28 |
1993-09-07 |
William J. Louis |
3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them
|
|
US4812448A
(en)
|
1984-10-22 |
1989-03-14 |
Knepper Paul A |
Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
|
|
US4757089A
(en)
|
1985-06-14 |
1988-07-12 |
Massachusetts Eye And Ear Infirmary |
Increasing aqueous humor outflow
|
|
US5075323A
(en)
|
1988-08-24 |
1991-12-24 |
Aktiebolaget Hassle |
Compounds including omeprazole in the treatment of glaucoma
|
|
US5260059A
(en)
|
1989-04-14 |
1993-11-09 |
The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University |
Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
|
|
US6372249B1
(en)
|
1991-12-16 |
2002-04-16 |
Baylor College Of Medicine |
Senscent cell-derived inhibitors of DNA synthesis
|
|
US5464866A
(en)
|
1992-08-17 |
1995-11-07 |
Alcon Laboratories, Inc. |
Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
|
|
US5545626A
(en)
|
1994-01-19 |
1996-08-13 |
The Trustees Of Columbia University In The City Of New York |
Method of treating glaucoma with oligonucleotides
|
|
US5585401A
(en)
|
1994-12-09 |
1996-12-17 |
The Reents Of The University Of California |
Method for enhancing outflow of aqueous humor in treatment of glaucoma
|
|
US20020055536A1
(en)
|
1996-09-26 |
2002-05-09 |
Dewitte Robert S. |
System and method for structure-based drug design that includes accurate prediction of binding free energy
|
|
US6489307B1
(en)
|
1998-09-14 |
2002-12-03 |
University Of Florida |
Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use
|
|
EP2314700A1
(en)
|
1999-01-28 |
2011-04-27 |
Medical College of Georgia Research Institute, Inc |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
|
|
US6365576B1
(en)
|
1999-06-24 |
2002-04-02 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Method for inhibiting herpes infection
|
|
CZ302719B6
(cs)
|
2000-12-01 |
2011-09-21 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
|
|
US20020165158A1
(en)
|
2001-03-27 |
2002-11-07 |
King George L. |
Methods of modulating angiogenesis
|
|
US20040209832A1
(en)
|
2001-11-30 |
2004-10-21 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
|
US20050148530A1
(en)
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
|
US20070049543A1
(en)
|
2001-05-18 |
2007-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
|
|
WO2003059267A2
(en)
|
2001-12-21 |
2003-07-24 |
Rhode Island Hospital |
SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF
|
|
US7294504B1
(en)
|
2001-12-27 |
2007-11-13 |
Allele Biotechnology & Pharmaceuticals, Inc. |
Methods and compositions for DNA mediated gene silencing
|
|
GB2406568B
(en)
|
2002-02-20 |
2005-09-28 |
Sirna Therapeutics Inc |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
AU2003207708A1
(en)
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
|
JP2006500910A
(ja)
|
2002-04-18 |
2006-01-12 |
アキュイティ ファーマシューティカルズ、インク． |
Ｃｎｓと眼の標的遺伝子を特異的に調節するための手段と方法及びその同定法
|
|
US20040115641A1
(en)
|
2002-12-11 |
2004-06-17 |
Isis Pharmaceuticals Inc. |
Modulation of ROCK 1 expression
|
|
JP2005533503A
(ja)
|
2002-07-24 |
2005-11-10 |
イミューソル インコーポレイテッド |
新規なｓｉＲＮＡ遺伝子ライブラリー、その製造方法及び使用
|
|
AU2003254162A1
(en)
|
2002-07-24 |
2004-02-09 |
Immusol Incorporated |
Single promoter system for making sirna expression cassettes and expression libraries using a polymerase primer hairpin linker
|
|
IL166546A0
(en)
|
2002-08-05 |
2006-01-15 |
Atugen Ag |
Further novel forms of interfering ran molecules
|
|
US20040029275A1
(en)
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
|
WO2004029212A2
(en)
|
2002-09-25 |
2004-04-08 |
University Of Massachusetts |
In vivo gene silencing by chemically modified and stable sirna
|
|
KR20050083855A
(ko)
|
2002-11-01 |
2005-08-26 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
ＨＩＦ-1 알파의 ｓｉＲＮＡ 억제를 위한 조성물 및 방법
|
|
DE10322662A1
(de)
|
2002-11-06 |
2004-10-07 |
Grünenthal GmbH |
Wirksame und stabile DNA-Enzyme
|
|
DK2284266T3
(da)
|
2002-11-14 |
2014-01-13 |
Thermo Fisher Scient Biosciences Inc |
sIRNA-MOLEKYLE MOD TP53
|
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
|
US20060257851A1
(en)
|
2002-11-26 |
2006-11-16 |
Itzhak Bentwich |
Bioinformatically detectable group of novel viral regulatory genes and uses thereof
|
|
US20040167090A1
(en)
|
2003-02-21 |
2004-08-26 |
Monahan Sean D. |
Covalent modification of RNA for in vitro and in vivo delivery
|
|
GB0307206D0
(en)
|
2003-03-28 |
2003-04-30 |
Axordia Ltd |
Hyperproliferation
|
|
US20040198640A1
(en)
|
2003-04-02 |
2004-10-07 |
Dharmacon, Inc. |
Stabilized polynucleotides for use in RNA interference
|
|
WO2004099372A2
(en)
|
2003-05-01 |
2004-11-18 |
University Of Florida |
Anti-scarring ribozymes and methods
|
|
US20040224405A1
(en)
|
2003-05-06 |
2004-11-11 |
Dharmacon Inc. |
siRNA induced systemic gene silencing in mammalian systems
|
|
US20060241072A1
(en)
|
2003-06-20 |
2006-10-26 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds for use in gene modulation
|
|
CA2541299A1
(en)
|
2003-10-07 |
2005-04-14 |
Renovis, Inc. |
Amide compounds as ion channel ligands and uses thereof
|
|
WO2005045037A2
(en)
|
2003-10-23 |
2005-05-19 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
KR20050039573A
(ko)
|
2003-10-23 |
2005-04-29 |
주식회사 태평양 |
티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물
|
|
US20050208658A1
(en)
|
2003-11-21 |
2005-09-22 |
The University Of Maryland |
RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
|
|
KR20180037067A
(ko)
*
|
2003-12-03 |
2018-04-10 |
코다 테라퓨틱스 (엔지) 리미티드 |
코넥신에 표적화된 안티센스 화합물 및 그의 사용 방법
|
|
US7544803B2
(en)
|
2004-01-23 |
2009-06-09 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
|
CA2555335A1
(en)
|
2004-02-05 |
2005-08-25 |
Intradigm Corporation |
Rnai therapeutics for treatment of eye neovascularization diseases
|
|
GB0403600D0
(en)
|
2004-02-18 |
2004-03-24 |
Trinity College Dublin |
Methods and reagents for treating disease
|
|
EP2899278A1
(en)
|
2004-03-12 |
2015-07-29 |
Alnylam Pharmaceuticals Inc. |
iRNA agents targeting VEGF
|
|
KR101147147B1
(ko)
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
|
WO2005117938A2
(en)
|
2004-04-13 |
2005-12-15 |
Regents Of The University Of Minnesota |
Methods of treating ocular conditions
|
|
WO2006002361A2
(en)
|
2004-06-24 |
2006-01-05 |
Incyte Corporation |
2-methylpropanamides and their use as pharmaceuticals
|
|
CA2576233C
(en)
|
2004-08-10 |
2016-03-15 |
Alnylam Pharmaceuticals, Inc. |
Conjugate comprising an antagomir and a ligand
|
|
EP2298892A3
(en)
|
2004-08-23 |
2011-11-16 |
Sylentis S.A.U. |
Treatment of eye disorders characterized by an elevated intraocular pressure by siRNAs
|
|
TW200639252A
(en)
|
2005-02-01 |
2006-11-16 |
Alcon Inc |
RNAi-mediated inhibition of ocular hypertension targets
|
|
AU2006223131A1
(en)
|
2005-03-11 |
2006-09-21 |
Alcon, Inc. |
RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
|
|
GB0521351D0
(en)
*
|
2005-10-20 |
2005-11-30 |
Genomica Sau |
Modulation of TRPV expression levels
|
|
JP2010501188A
(ja)
*
|
2006-08-24 |
2010-01-21 |
アルコン リサーチ， リミテッド |
ＩＯＰに関連した病態の処置のためのグレムリンのＲＮＡｉ媒介阻害
|
|
WO2009023025A1
(en)
|
2007-08-13 |
2009-02-19 |
Board Of Trustees Of Southern Illinois University |
Methods for treatment and prevention of ototoxicity by sirna
|
|
TW200927192A
(en)
*
|
2007-11-19 |
2009-07-01 |
Alcon Res Ltd |
Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
|
|
CN201337650Y
(zh)
*
|
2009-01-06 |
2009-11-04 |
河北科技大学 |
一次性药用单剂量液体容器
|
|
EP2390327A1
(en)
*
|
2010-05-27 |
2011-11-30 |
Sylentis S.A. |
siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
|